This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Special Investigation in Patients With Ulcerative Colitis

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
AbbVie Identifier:
First received: September 18, 2013
Last updated: July 24, 2017
Last verified: July 2017

This investigation will be conducted to obtain the following information regarding the use of Humira 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Ulcerative Colitis.

  1. Unknown adverse reactions (in particular, clinically significant)
  2. Incidence and conditions of occurrence of adverse reactions in clinical practice
  3. Factors likely to affect the safety and effectiveness

Ulcerative Colitis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Special Investigation in Patients With Ulcerative Colitis

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Number of patients with adverse events [ Time Frame: Up to Week 52 ]
    Number of patients with adverse events with evaluation beginning upon administration of Humira

Secondary Outcome Measures:
  • Full Mayo score [ Time Frame: Up to week 52 ]
  • Partial Mayo score [ Time Frame: Up to week 52 ]
  • C-reactive Protein [ Time Frame: Up to week 52 ]
  • Mayo endoscopic sub-score [ Time Frame: Up to week 52 ]

Estimated Enrollment: 1500
Study Start Date: August 9, 2013
Estimated Study Completion Date: March 31, 2018
Estimated Primary Completion Date: July 28, 2017 (Final data collection date for primary outcome measure)
Humira 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration


Ages Eligible for Study:   up to 99 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients for the first time receiving Humira for the treatment of Ulcerative Colitis

Inclusion Criteria:

  • Patients receiving Humira for the first time for the treatment of Ulcerative Colitis

Exclusion Criteria:

Contraindications according to the Package Insert include patients who have any of the following:

  • serious infections
  • tuberculosis
  • a history of hypersensitivity to any ingredient of Humira
  • demyelinating disease or a history of demyelinating disease
  • congestive cardiac failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01947816

  Show 406 Study Locations
Sponsors and Collaborators
Study Director: Osamu Mikami, MD AbbVie GK
  More Information

Additional Information:
Responsible Party: AbbVie Identifier: NCT01947816     History of Changes
Other Study ID Numbers: P14-190
Study First Received: September 18, 2013
Last Updated: July 24, 2017

Keywords provided by AbbVie:
Ulcerative Colitis

Additional relevant MeSH terms:
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases processed this record on September 19, 2017